Anti-BRD2 Antibody

This polyclonal IgG reagent from Antibodies.com, supplied at 200 µl, targets bromodomain-containing protein 2 (BRD2), a member of the BET family of epigenetic readers that bind acetylated lysine residues on histones and modulate chromatin dynamics and gene transcription. Raised in rabbit and supplied unconjugated, the antibody is validated for Western blot (WB) and immunohistochemistry (IHC) workflows, with reactivity confirmed in human samples.

BRD2 has emerged as a prominent research target because of its involvement in cell cycle progression, transcriptional elongation, and inflammatory gene regulation. Aberrant BRD2 activity has been linked to B-cell lymphoma, acute myeloid leukemia, and other proliferative disorders, and the protein is the subject of intensive investigation using BET inhibitors such as JQ1 in oncology and epigenetics research. Investigators deploy this reagent to assess BRD2 expression in tumor-derived cell lines, characterize its chromatin association, and dissect bromodomain-dependent signaling in primary tissue sections.

Provided as a single-use vial, the antibody supports chromatin biology, cancer biology, and immunology workflows where interrogation of acetylation-dependent transcriptional programs is required.